Abstract
Translationally controlled tumor protein (TCTP) is a multifunctional protein that plays a wide variety of physiological and pathological roles, including as a cytoplasmic repressor of Na,K-ATPase, an enzyme pivotal in maintaining Na+ and K+ ion gradients across the plasma membrane, by binding to and inhibiting Na,K-ATPase. Studies with transgenic mice overexpressing TCTP (TCTP-TG) revealed the pathophysiological significance of TCTP in the development of systemic arterial hypertension. Overexpression of TCTP and inhibition of Na,K-ATPase result in the elevation of cytoplasmic Ca2+ levels, which increases the vascular contractility in the mice, leading to hypertension. Furthermore, studies using an animal model constructed by multiple mating of TCTP-TG with apolipoprotein E knockout mice (ApoE KO) indicated that TCTP-induced hypertension facilitates the severity of atherosclerotic lesions in vivo. This review attempts to discuss the mechanisms underlying TCTP-induced hypertension and related diseases gleaned from studies using genetically altered animal models and the potential of TCTP as a target in the therapy of hypertension-related pathological conditions.
Original language | English |
---|---|
Article number | 2722 |
Journal | Biomedicines |
Volume | 10 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2022 |
Bibliographical note
Publisher Copyright:© 2022 by the authors.
Keywords
- ApoE KO
- Na,K-ATPase
- TCTP
- TCTP-TG
- TCTP-overexpressing transgenic mice
- apolipoprotein E knockout mice
- atherosclerosis
- hypertension
- translationally controlled tumor protein